Immunoprecise Stock Price, News & Analysis

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutics company, announced that CEO Dr. Jennifer Bath will present at Maxim Group's 2025 Virtual Tech Conference on Tuesday, June 3rd at 11:00 AM EDT. The conference, running from June 3rd to 5th, will focus on technological disruption across various industries, with particular emphasis on Quantum Computing and AI applications.

The virtual event, hosted on the M-Vest Platform, will feature discussions between Maxim Senior Analysts and company executives about how emerging growth companies are leveraging advanced technologies for future positioning. The conference will explore innovation impacts across healthcare, drones, consumer IoT, business solutions, and gaming & entertainment sectors.

ImmunoPrecise Antibodies (NASDAQ:IPA) has announced breakthrough results for its LENSai™ AI platform's epitope mapping capabilities. The platform matched the accuracy of gold-standard x-ray crystallography in antibody-antigen analysis, but delivers results in hours instead of months. In benchmarking tests across five antibody-antigen pairs, LENSai achieved predictive scores (AUC 0.79-0.89) comparable to or better than traditional wet-lab methods.

The platform's ability to provide accurate epitope mapping insights using only sequence data represents a significant advancement in computational biology and antibody discovery, where industry failure rates exceed 95%. This development aligns with FDA's move to phase out animal testing requirements for biologics and offers a more ethical, scalable approach to biotherapeutic discovery.

ImmunoPrecise Antibodies (NASDAQ: IPA) has expressed strong support for the FDA's decision to phase out animal testing requirements for monoclonal antibodies and pharmaceutical products. The company's AI platform, LENSai™, aligns with this regulatory shift by providing validated AI-driven methodologies that support New Approach Methodologies (NAMs).

The platform offers three key capabilities:

• Safety and Toxicity Prediction through AI analytics mapping drug interactions across the human proteome
• Immunogenicity Screening to identify immune response risks and optimize patient strategies
• Knowledge Graphs for Drug Efficacy that integrate biological data for precise drug interaction predictions

According to CEO Dr. Jennifer Bath, this transition aims to streamline preclinical workflows, reduce development costs, and maintain higher ethical standards while ensuring regulatory compliance.

ImmunoPrecise Antibodies (IPA) reported Q3 FY25 financial results, securing an $8-10M strategic partnership for co-developing Antibody-Drug Conjugates and bispecific antibodies. The company expanded AI infrastructure through collaborations with Vultr and GPU technology providers.

Key financial highlights include:

• Revenue remained stable at $6.2M
• BioStrand showed 131.8% YoY revenue growth with 97% gross margin
• Net loss of $21.5M ($0.66 per share) vs $2.7M loss in FY24 Q3
• Cash position of $12.9M as of January 31, 2025

Notable developments include headquarters relocation to Austin, Texas, completion of an $8.8M ATM equity raise, and full conversion of Yorkville debenture. The company recorded a $21.2M impairment charge related to BioStrand's intangible assets.

ImmunoPrecise Antibodies (NASDAQ: IPA) has entered into a strategic partnership with a leading biotechnology company to develop Antibody-Drug Conjugates (ADCs) and bispecific antibodies for cancer treatment. The collaboration, valued at $8 million with potential expansion to $10 million, will span 18-24 months.

The partnership integrates IPA's proprietary B-cell Select™ platform and AI-driven discovery capabilities to enhance therapeutic development efficiency. The scope includes discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics, focusing on developing highly selective cancer treatments.

The project combines IPA's multi-omics AI-driven modeling and discovery platform with B-cell Select™ technology to optimize therapeutic selection and accelerate lead development. Work has already commenced, utilizing IPA's proprietary platforms including LENSai™ technology to advance targeted cancer therapeutics development.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered antibody discovery and development company, has announced the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. The release date has been moved from March 13 to March 28, 2025, with an earnings call scheduled for 10:30 AM Eastern Time on the same day.

The delay is attributed to providing additional time for auditors to complete necessary reviews and audit requirements, specifically focusing on valuation calculations of goodwill and intangible assets. This extension aims to ensure accurate financial data representation and full regulatory compliance.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered antibody discovery and development company, has scheduled its third quarter fiscal year 2025 financial results announcement and business update for March 13, 2025. The company will release its financial results via press release followed by a conference call and webcast at 10:30 AM ET.

The earnings call will include a management presentation and a Q&A session. Participants can join through various channels including USA/International toll line (+1-646-307-1963) or toll-free numbers (800-715-9871 for USA and Canada) using Conference ID 3224490. A webcast will be available through the company's IR events page.

ImmunoPrecise Antibodies (NASDAQ: IPA) has announced a strategic collaboration with RIBOPRO to enhance therapeutic antibody discovery by combining RIBOPRO's mRNA and lipid nanoparticle (LNP) technologies with IPA's AI-powered discovery capabilities.

The partnership aims to overcome challenges in antigen expression during antibody discovery by utilizing RIBOPRO's expertise in mRNA sequence optimization and LNP-based delivery alongside IPA's advanced B-cell screening, single-cell analysis, and deep-learning AI workflows.

This integration of mRNA immunization into IPA's discovery pipeline is expected to improve antigen presentation and immune responses, potentially accelerating the development of novel therapeutics.